Table 1

Demographics and clinical characteristics of study population

Placebo (n = 16)Sitagliptin (n = 16)
Day 11 MonthDay 11 Month
Demographics
 Age (years)59.3 ± 8.860.4 ± 7.6
 Males9 (56.3)11 (68.8)
 Ethnicity
  Caucasian8 (50)12 (75)
  South Asian4 (25)2 (12.5)
  Black1 (6.3)1 (6.3)
  Other3 (18.7)2 (6.2)
 Diabetes duration (years)8.50 (5.5, 14.0)6.0 (3.0, 10.0)
 Metformin use14 (87.5)14 (87.5)12 (75)12 (75)
 Sulfonylurea use6 (37.5)6 (37.5)3 (18.8)3 (18.8)
 Insulin use4 (25)4 (25)4 (25)4 (25)
 Hypertension duration (years)11.4 ± 10.16.8 ± 8.9
 RAAS inhibition16 (100)16 (100)16 (100)16 (100)
 Diuretics6 (37.5)6 (37.5)5 (31.3)5 (31.3)
 CCB5 (31.3)5 (31.3)3 (18.8)3 (18.8)
 Statin11 (68.8)11 (68.8)9 (56.3)9 (56.3)
 CVD1 (6.3)1 (6.3)4 (25)4 (25)
Clinical characteristics
 Hematocrit0.38 ± 0.040.36 ± 0.040.39 ± 0.020.37 ± 0.03
 HbA1c (%) 7.31 ± 0.84 7.18 ± 0.97 7.18 ± 0.796.82 ± 0.82
 HbA1c (mmol/mol)56 ± 9.255 ± 10.655 ± 8.651 ± 9.0
 Creatinine (mmol/L)68.6 ± 9.066.9 ± 7.570.6 ± 7.867.8 ± 8.9
 eGFR (CKD-EPI) (mL/min/1.73 m2)94.2 ± 11.495.6 ± 12.394.1 ± 7.296.4 ± 6.7
 BMI (kg/m2)30.22 ± 6.9630.16 ± 7.0231.69 ± 5.4931.70 ± 5.63
 SBP (mmHg)124 ± 14123 ± 14123 ± 13121 ± 9
 DBP (mmHg)71 ± 873 ± 771 ± 873 ± 7
 HR (bpm)74 ± 1468 ± 1274 ± 1468 ± 12
 MAP (mmHg)86 ± 989 ± 887 ± 988 ± 7
  • Data are expressed as n (%), mean ± SD, or median (interquartile range).

  • CCB, calcium channel blocker; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated GFR; HR, heart rate; MAP, mean arterial pressure.